New FDA guidance clarifies potency assays for cell and gene therapy makers, easing development from early programs to IND ...

By leveraging a “dare to share” philosophy, the life science ecosystem provides a platform for scientists and companies to ...

Earlier this week, contract development and manufacturing organization (CDMO) Shilpa announced it will invest $50 million to ...

The BioVentureHub is one of the country’s many platforms that open lines of communication between companies to share ideas ...

Verigraft is developing decellularized vein grafts to treat chronic venous insufficiency without immunosuppression, with trials underway.

Brian Gazaille is managing editor of the BioProcess International publication. In this role, he works closely with biopharmaceutical scientists to help them communicate their insights clearly and ...

Industrial manufacturing of recombinant therapeutic proteins using Chinese hamster ovary (CHO) cells is a process dominated by multiple levels of selection, such as selection of the right therapeutic ...

International contract development and manufacturing organization (CDMO) Samsung Biologics announced the signing of a US$262 million manufacturing agreement with an unnamed European pharmaceutical ...

Vaccines based on recombinant proteins represent a diverse class of immunological products, with antigenic proteins exhibiting significant variability depending on the target. Such proteins can differ ...